Spectrum of neutralizing sera in macaques immunized with either HIV-1B RU/HBsAg or HIV-1 MN/HBsAg hybrid particles.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Spectrum of neutralizing sera in macaques immunized with either HIV-1B RU/HBsAg or HIV-1 MN/HBsAg hybrid particles.

Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 128. Unique Identifier : AIDSLINE PRIM10/93200971
Schlienger K; Mancini M; Riviere Y; Tiollais P; Michel ML; Unite de Recombinaison et Expression Genetique, Institut; Pasteur, Paris, France.

Abstract: Hepatitis B surface antigen (HBsAg) produced by recombinant DNA technology is now largely and safely used for worldwide hepatitis B vaccination. We recently reported that recombinant HIV/HBsAg particles presenting the HIV-1 BRU envelope principal neutralizing determinant (PND) on their surface allowed us to generate proliferative T-cell responses, cellular cytotoxicity and neutralizing antibodies in immunized rhesus monkeys. Because HIV-1 MN has a more common PND sequence and because antibodies to MN-like PNDs are highly prevalent in HIV-1-infected humans' sera when compared to HIV-1 BRU, we have constructed an HBsAg chimera carrying the HIV-1 MN PND. Four cynomolgus monkeys received 3 intradermic injections at 1 month interval and one boost 4 months later of either hybrid HIV-1 MN/HBsAg particles or native HBsAg particles (1 control animal) in incomplete Freund's adjuvant. Serum obtained from HIV-1 BRU/HBsAg and HIV-1 MN/HBsAg vaccinated animals were compared for their ability to neutralize HIV-1 BRU, HIV-1 MN and HIV-1 RF at different times during the immunization regimen. We also looked for the presence of cytotoxic T lymphocytes towards autologous B lymphoblastoid target cells infected by gp 160 (HIV-1 MN) expressing recombinant vaccinia viruses. The effective presentation of HIV-1 MN and HIV-1 BRU PNDs by HBsAg particles may offer a new approach to the development of an AIDS multivalent subunit vaccine, if it is capable of inducing neutralizing antibodies and cellular responses against a wide range of HIV-1 isolates.

Keywords: Animal Antibodies, Viral/*BLOOD B-Lymphocytes/IMMUNOLOGY Chimera Cytotoxicity, Immunologic Gene Products, env/IMMUNOLOGY Hepatitis B Antibodies/*BLOOD Hepatitis B Surface Antigens/*IMMUNOLOGY HIV Antibodies/*BLOOD HIV-1/*IMMUNOLOGY Lymphocyte Transformation Macaca fascicularis Macaca mulatta Neutralization Tests Protein Precursors/IMMUNOLOGY Recombinant Proteins/IMMUNOLOGY T-Lymphocytes/*IMMUNOLOGY T-Lymphocytes, Cytotoxic/IMMUNOLOGY Vaccines, Synthetic/*PHARMACOLOGY ABSTRACT
930630
M9361049

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .